Practical Considerations for the Use of Subcutaneous Treatment in the Management of Dyslipidaemia.

ABSTRACT: Suboptimal drug adherence represents a major challenge to effective primary and secondary prevention of cardiovascular disease. While adherence is influenced by multiple considerations, polypharmacy and dosing frequency appear to be rate-limiting factors in patient satisfaction and subsequent adherence. The cardiovascular and metabolic therapeutic areas have recently benefited from a number of advances in drug therapy, in particular protease proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incretin-based therapies, respectively. These drugs are administered subcutaneously and offer efficacious treatment options with reduced dosing frequency. Whilst patients with diabetes and diabetologists are well initiated to injectable therapies, the cardiovascular therapeutic arena

SUBMITTER: Boccara F 

PROVIDER: S-EPMC5565663 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature